4.6 Review

Rheumatoid arthritis: Extra-articular manifestations and comorbidities

期刊

AUTOIMMUNITY REVIEWS
卷 20, 期 4, 页码 -

出版社

ELSEVIER
DOI: 10.1016/j.autrev.2021.102776

关键词

Rheumatoid arthritis; Comorbidity; Extra-articular manifestation; Complications

向作者/读者索取更多资源

Synovitis is the primary manifestation of rheumatoid arthritis (RA), but many extra-articular manifestations and comorbidities are likely due to the chronic, complex nature of the disease. Cardiovascular disease is the leading cause of death in RA patients, with increased risks of myocardial infarction and CV mortality. Other common causes of death in RA patients include respiratory disease and neurological issues, with evidence linking systemic inflammation to Alzheimer's disease and vascular dementia. In order to reduce morbidity and mortality, physicians must actively manage RA disease activity and monitor for potential risk factors and associated conditions.
Although synovitis is the pathological hallmark of rheumatoid arthritis (RA), many extra-articular manifestations (EMs) and comorbidities likely occur due to the complex, chronic, inflammatory, and autoimmune features of RA. Cardiovascular (CV) disease is the most common cause of death in patients with RA. Compared to the general population, patients with RA have twice the risk of myocardial infarction and up to 50% increased CV mortality risk. Severe and prolonged disease activity, genetics, and inflammation (e.g. CRP, ACPA, cytokines, matrix-degrading enzymes) play important roles in CV disease and atheroscleroticdamage. The second major cause of death in patients with RA is respiratory disease, which occurs in 30-40% of patients. RA may affect the lung interstitium, airways, and pleurae, while pulmonary vascular involvement is less frequent. Central and peripheral nervous system involvement is usually due to small vessel vasculitis, joint damage, or drug toxicity. There is also evidence that microvascular cerebral damage caused by systemic inflammation is associated with the development of Alzheimer's disease and vascular dementia. Some observational studies have hinted how Disease Modified Anti-Rheumatic Drugs and biologics could reduce the incidence of dementia. Primary gastrointestinal and renal involvements are rare and often relate to drug therapy. To minimize morbidity and mortality, physicians must manage RA disease activity (treat-to-target) and monitor risk factors and concomitant conditions (e.g. smoking cessation; weight regulation; monitoring blood pressure, lipids, thyroid hormone, folic acid and homocysteine; screening for depression, anxiety, atlantoaxial instability, and atherosclerosis). This article aims to provide an overview of the most prevalent and important EMs and comorbidities associated with RA.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据